{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'List of Tables', 'Table 1.', 'Examples of Strong CYP3A4 Inhibitors', '41', 'Table 2.', 'Clinical Laboratory Tests', '49', 'Table 3.', 'Identity of Investigational Products', '65', 'Table 4.', 'Dose Reductions for Blinded Investigational Product (IP)', '70', 'Table 5.', 'Dose Reductions and Discontinuation for Unacceptable Toxicities', '71', 'Table 6.', 'Recommended Management of Photosensitivity', '87', 'List of Figures', 'Figure 1.', 'Study Schema', '33', 'Figure 2.', 'Adverse Event Collection', '81', 'Figure 3.', 'Diagram of Hierarchical Testing of Primary and Secondary', 'Endpoints', '104', 'List of Appendices', 'Appendix A.', 'Responsibilities of the Clinical Investigator', '117', 'Appendix B.', 'List of Protocol Signatories', '119', 'Appendix C.', 'Study Activities', '120', 'Appendix D.', 'Performance Status Scales Conversion', '127', 'Appendix E.', 'Calculated Creatinine Clearance Using Modified Cockcroft-Gault', 'Equation', '128', 'Appendix F.', 'New York Heart Association Classification', '129', 'Appendix G.', 'Response Evaluation Criteria for Solid Tumors (RECIST) V 1.1', 'for Tumor Response', '130', 'Appendix H.', 'CTCAE V 4.0 Grading of Relevant AEs', '137', 'Appendix I.', 'Fluid Retention Questionnaire', '142', 'Appendix J.', 'Adverse Events Expected Due to SCLC or Progression of SCLC', '144', 'Appendix K.', 'Protocol Amendment: List of Changes', '146', '25']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '3.0', 'Introduction', '3.1', 'Small Cell Lung Cancer', 'Small cell lung cancer (SCLC) is an important unmet medical need, representing 15 -', '20% of the 220,000 annual new cases of lung cancer. 1,2 SCLC arises from epithelial cells', 'with neuroendocrine differentiation. Historically, SCLC has been staged using the', 'Veterans Administration (VA) staging system as limited versus extensive stage disease,', 'the former being defined as disease limited to the chest that can be encompassed by a', 'radiation field while the latter includes all other cases. Approximately one-third of newly', 'diagnosed patients will have limited stage disease while the rest will be extensive.', 'Systemic chemotherapy remains the cornerstone of therapy for all stages of SCLC.', 'Standard initial chemotherapy for all patients with a suitable performance status consists', 'of a platinum salt (carboplatin or cisplatin) in combination with a second agent, usually', 'etoposide or irinotecan. For patients with limited stage disease, concurrent or sequential', 'involved-field thoracic radiotherapy is indicated. Response rates to initial therapy are', 'high, ranging from 70 - 90% for limited stage and 60 - 70% for extensive stage; however,', 'responses are typically not durable and recurrence rates are high in the limited stage', 'disease and nearly universal in the extensive stage disease, leading to median survivals of', '14 - 20 months and 9 - 11 months, respectively.\u00b3', 'Extensive stage disease subjects achieving SD or better during first-line platinum-based', 'therapy have median progression-free survival (PFS) of approximately 2.1 - 2.3 months', 'and median os of approximately 6.9 - 8.9 months from the completion of first-line', 'therapy. 4,5 Exploration of clinical benefit maintenance strategies in extensive disease', 'SCLC with the goal of prolonging PFS and OS after completion of first-line standard', 'therapies is therefore warranted.', '3.2', 'Delta-Like Protein 3', 'Delta-like protein 3 (DLL3) is an atypical, inhibitory ligand of the Notch receptor family,', 'discovered by AbbVie Stemcentrx scientists as a novel therapeutic target in SCLC and', '26']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'other high-grade neuroendocrine carcinomas. It was identified by whole transcriptome', 'sequencing of tumor initiating cells (TICs) isolated from SCLC and large cell', 'neuroendocrine cancer (LCNEC) patient-derived xenografts (PDXs), and found to be', 'expressed in the majority of SCLC and LCNEC tumors, but with no detectable protein', 'expression in normal tissues or non-neuroendocrine tumor types. 6 DLL3 has been', 'implicated in the regulation of cell fate decisions during development, and likely acts as', 'an oncogene in high-grade neuroendocrine tumors where it is a downstream', 'transcriptional target of the achaete-scute homolog 1 (ASCL1) transcription factor in', 'SCLC tumor cells, and acts to inhibit the Notch receptor pathway, thereby facilitating', 'neuroendocrine tumorigenesis. 6-8', '3.3', 'Rovalpituzumab Tesirine', 'Rovalpituzumab tesirine (SC16LD6.5) is a DLL3-targeted antibody-drug conjugate', '(ADC) consisting of the humanized DLL3-specific IgG1 monoclonal antibody SC16; the', 'DNA cross-linking agent SC-DR002 (D6.5); and a protease-cleavable linker that', 'covalently links SC DR002 to SC16. The primary mechanism of rovalpituzumab tesirine', 'is binding of the ADC to DLL3 on target-expressing cells, followed by internalization of', 'the ADC-DLL3 complex and release of SC-DR002 via proteolytic cleavage in late', 'endosomes. Interstrand crosslinks of cellular DNA induced by intercalated SC-DR002', 'leads to cellular cytotoxicity.', 'In the Phase 1 first in human study of rovalpituzumab tesirine (Study SCRX16-001) the', 'best overall response (confirmed) for all SCLC subjects (dose escalation, retreatment, and', 'maintenance cohorts) was retrospectively assessed by the Independent Review Committee', '(IRC) by RECIST v1.1 criteria. The ORR (confirmed) was 16% (95% CI: 7.35, 27.42),', 'with 12% achieving PR. The clinical benefit rate (CBR) was 59% (95% CI: 44.93,', '71.40). The median duration of response by the IRC was 1.7 months (95% CI: 0.03,', '3.06). The median progression-free survival by the IRC was 3.0 months (95% CI: 2.56,', '3.84), with a probability of progression-free survival at 12 weeks of 52% (95% CI: 39,', '63). The median overall survival was 4.3 months (95% CI: 3.22, 5.65). The probability', 'of overall survival at 12 weeks was 69% (95% CI: 52,81). In DLL3-positive (> 1%', '27']\n\n###\n\n", "completion": "END"}